Flash e-reader

 Go to e-reader chapter








Table 6.6g

Immunosuppression Use for Maintenance Between Discharge

and One Year Following Transplantation, 1999 to 2008

Recipients with Pancreas Transplant Alone (PTA) Transplants

  Year of Transplant
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Transplants 139 134 168 180 160 183 199 174 210 223
Tx with Follow-up Immunosuppression Info 109 96 122 140 115 137 149 125 152 159
Corticosteroids Any in Category 100.0% 96.9% 92.6% 86.4% 56.5% 58.4% 55.0% 59.2% 59.9% 63.5%
Steroids 100.0% 96.9% 92.6% 86.4% 56.5% 58.4% 55.0% 59.2% 59.9% 63.5%
Cyclosporine Any in Category 8.3% 8.3% 5.7% 8.6% 7.0% 3.6% 2.7% 2.4% 3.9% 1.3%
Sandimmmune 0.0% 2.1% 0.0% 0.0% 0.0% 0.0% 1.3% 0.8% 0.7% 0.0%
Neoral 8.3% 5.2% 5.7% 6.4% 6.1% 3.6% 1.3% 1.6% 3.3% 1.3%
Gengraf 0.0% 1.0% 0.0% 1.4% 0.9% 0.0% 0.0% 0.0% 0.0% 0.0%
Eon 0.0% 0.0% 0.0% 0.7% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Tacrolimus Any in Category 96.3% 95.8% 98.4% 95.0% 84.3% 85.4% 97.3% 98.4% 95.4% 99.4%
Tacrolimus 96.3% 95.8% 98.4% 95.0% 84.3% 85.4% 97.3% 97.6% 95.4% 99.4%
Everolimus 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.8% 0.0% 0.0%
Antimetabolites Any in Category 93.6% 81.3% 73.8% 63.6% 60.0% 60.6% 63.8% 60.8% 62.5% 69.2%
Mycophenolate Mofetil 91.7% 76.0% 70.5% 63.6% 59.1% 54.7% 55.7% 52.8% 52.0% 60.4%
Mycophenolate Sodium 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 4.7% 6.4% 6.6% 8.2%
Azathioprine 1.8% 5.2% 3.3% 0.0% 0.9% 5.8% 3.4% 1.6% 3.9% 0.6%
mTOR Inhibitors Any in Category 17.4% 27.1% 16.4% 32.9% 24.3% 26.3% 27.5% 28.8% 23.7% 15.7%
Sirolimus 17.4% 27.1% 16.4% 32.9% 24.3% 26.3% 27.5% 28.8% 23.7% 15.7%
Everolimus 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%


Source: OPTN/SRTR Data as of October 1, 2010.

Percentages are calculated based on the total number of patients with any immunosuppression use between discharge and one year following transplantation.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within

the same category.